Prevalence of Plasmodium falciparum Pfcrt and Pfmdr1 alleles in settings with different levels of Plasmodium vivax co-endemicity in Ethiopia.
Adolescent
Adult
Alleles
Antimalarials
/ pharmacology
Artemether, Lumefantrine Drug Combination
/ pharmacology
Child
Chloroquine
/ pharmacology
Drug Resistance
Endemic Diseases
Ethiopia
/ epidemiology
Female
Haplotypes
Humans
Malaria, Falciparum
/ complications
Malaria, Vivax
/ complications
Male
Membrane Transport Proteins
/ genetics
Multidrug Resistance-Associated Proteins
/ genetics
Plasmodium falciparum
/ classification
Plasmodium vivax
/ classification
Point Mutation
Polymorphism, Genetic
Prevalence
Protozoan Proteins
/ genetics
Young Adult
Artemether-Lumefantrine
Artemisinin resistance
Drug resistance
Ethiopia
Pfcrt
Pfmdr
Journal
International journal for parasitology. Drugs and drug resistance
ISSN: 2211-3207
Titre abrégé: Int J Parasitol Drugs Drug Resist
Pays: Netherlands
ID NLM: 101576715
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
02
05
2019
revised:
28
08
2019
accepted:
09
09
2019
pubmed:
21
9
2019
medline:
15
5
2020
entrez:
21
9
2019
Statut:
ppublish
Résumé
Plasmodium falciparum and P. vivax co-exist at different endemicity levels across Ethiopia. For over two decades Artemether-Lumefantrine (AL) is the first line treatment for uncomplicated P. falciparum, while chloroquine (CQ) is still used to treat P. vivax. It is currently unclear whether a shift from CQ to AL for P. falciparum treatment has implications for AL efficacy and results in a reversal of mutations in genes associated to CQ resistance, given the high co-endemicity of the two species and the continued availability of CQ for the treatment of P. vivax. This study thus assessed the prevalence of Pfcrt-K76T and Pfmdr1-N86Y point mutations in P. falciparum. 18S RNA gene based nested PCR confirmed P. falciparum samples (N = 183) collected through community and health facility targeted cross-sectional surveys from settings with varying P. vivax and P. falciparum endemicity were used. The proportion of Plasmodium infections that were P. vivax was 62.2% in Adama, 41.4% in Babile, 30.0% in Benishangul-Gumuz to 6.9% in Gambella. The Pfcrt-76T mutant haplotype was observed more from samples with higher endemicity of P. vivax as being 98.4% (61/62), 100% (31/31), 65.2% (15/23) and 41.5% (22/53) in samples from Adama, Babile, Benishangul-Gumuz and Gambella, respectively. However, a relatively higher proportion of Pfmdr1-N86 allele (77.3-100%) were maintained in all sites. The observed high level of the mutant Pfcrt-76T allele in P. vivax co-endemic sites might require that utilization of CQ needs to be re-evaluated in settings co-endemic for the two species. A country-wide assessment is recommended to clarify the implication of the observed level of variation in drug resistance markers on the efficacy of AL-based treatment against uncomplicated P. falciparum malaria.
Identifiants
pubmed: 31539706
pii: S2211-3207(19)30065-X
doi: 10.1016/j.ijpddr.2019.09.002
pmc: PMC6796752
pii:
doi:
Substances chimiques
Antimalarials
0
Artemether, Lumefantrine Drug Combination
0
Mdr1 protein, Plasmodium falciparum
0
Membrane Transport Proteins
0
Multidrug Resistance-Associated Proteins
0
PfCRT protein, Plasmodium falciparum
0
Protozoan Proteins
0
Chloroquine
886U3H6UFF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8-12Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Int J Parasitol Drugs Drug Resist. 2015 Jun 29;5(3):92-9
pubmed: 26236581
Antimicrob Agents Chemother. 2013 Feb;57(2):818-26
pubmed: 23208711
J Infect Dis. 2009 Mar 1;199(5):750-7
pubmed: 19210165
Malar J. 2018 Nov 7;17(1):413
pubmed: 30404640
Malar J. 2014 Jul 09;13:264
pubmed: 25007802
Malar J. 2014 Nov 18;13:438
pubmed: 25406667
PLoS Med. 2013;10(3):e1001398
pubmed: 23472056
Mol Cell Probes. 2006 Apr;20(2):100-4
pubmed: 16460912
Malar J. 2015 May 19;14:208
pubmed: 25986047
Clin Infect Dis. 2018 Jun 1;66(12):1883-1891
pubmed: 29304258
East Afr Med J. 2005 Aug;82(8):391-5
pubmed: 16261914
Malar J. 2014 Feb 06;13:48
pubmed: 24502664
Emerg Infect Dis. 2017 Mar;23(3):517-520
pubmed: 28221121
Malar J. 2014 Mar 27;13:120
pubmed: 24674605
Am J Trop Med Hyg. 2012 Feb;86(2):211-3
pubmed: 22302850
Malar J. 2010 Aug 07;9:226
pubmed: 20691106
Malar J. 2013 Aug 02;12:272
pubmed: 23914905
Malar J. 2011 Aug 02;10:214
pubmed: 21810256
Malar J. 2013 Nov 14;12:415
pubmed: 24225406
J Infect Dis. 2011 Oct 1;204(7):1120-4
pubmed: 21881128
N Engl J Med. 2001 Jan 25;344(4):257-63
pubmed: 11172152
Infect Dis Poverty. 2018 Nov 5;7(1):103
pubmed: 30392470
Lancet. 2004 Jul 31-Aug 6;364(9432):438-447
pubmed: 15288742
J Infect Dis. 2003 Jun 15;187(12):1870-5
pubmed: 12792863
J Clin Invest. 2004 Apr;113(8):1084-92
pubmed: 15085184
BMJ Glob Health. 2018 Oct 19;3(5):e000999
pubmed: 30397515
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Malar J. 2009 Oct 12;8 Suppl 1:S8
pubmed: 19818175
Malar J. 2018 Feb 20;17(1):84
pubmed: 29458380
Sci Rep. 2018 Aug 28;8(1):12951
pubmed: 30154519
Malar J. 2016 Dec 5;15(1):584
pubmed: 27919256
Malar J. 2013 Oct 30;12:377
pubmed: 24172030
PLoS Negl Trop Dis. 2017 Jul 26;11(7):e0005806
pubmed: 28746333
Trans R Soc Trop Med Hyg. 2019 Jun 1;113(6):305-311
pubmed: 30927007
PLoS One. 2018 Feb 1;13(2):e0191922
pubmed: 29390014
Am J Trop Med Hyg. 2014 Oct;91(4):833-843
pubmed: 25048375
Mol Biochem Parasitol. 1993 Apr;58(2):283-92
pubmed: 8479452
Malar Res Treat. 2016;2016:1240962
pubmed: 27047701
PLoS One. 2016 Mar 31;11(3):e0151565
pubmed: 27031231
Malar J. 2006 Jul 03;5:54
pubmed: 16817953
Malar J. 2014 Oct 18;13:411
pubmed: 25326079
J Infect Dis. 2005 Mar 15;191(6):1014-7
pubmed: 15717281
Antimicrob Agents Chemother. 2006 May;50(5):1893-5
pubmed: 16641472
J Infect Dis. 2014 Aug 1;210(3):344-53
pubmed: 24610872
Malar J. 2014 Jun 25;13:244
pubmed: 24964730